Hemogenyx Pharmaceuticals PLC (LON:HEMO) shares rose 6.1% during trading on Thursday . The company traded as high as GBX 2.60 ($0.03) and last traded at GBX 2.60 ($0.03). Approximately 190,000 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 8,010,000 shares. The stock had previously closed at GBX 2.45 ($0.03).

COPYRIGHT VIOLATION WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/hemogenyx-pharmaceuticals-hemo-stock-price-up-6-1/2669156.html.

About Hemogenyx Pharmaceuticals (LON:HEMO)

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants.

Read More: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.